Emerging Modalities: mRNA, RNAi, Radioligands, and Beyond

Introduction

The biotech landscape is being reshaped by several therapeutic modalities that did not exist or were not clinically viable a decade ago. For healthcare bankers, these emerging modalities represent the next wave of platform acquisitions, licensing deals, and biotech capital markets activity. Understanding the basic science, commercial economics, and competitive dynamics of each modality is increasingly important because modality expertise has become a differentiator in healthcare banking: the banker who can speak fluently about RNAi delivery challenges or radioligand supply chain constraints adds value that a generalist cannot match.

The COVID-19 pandemic validated mRNA as a therapeutic platform, but the technology's potential extends far beyond vaccines. mRNA therapies instruct cells to produce specific proteins by delivering synthetic messenger RNA that is translated by the cell's own machinery. This means any disease caused by a missing, deficient, or abnormal protein is theoretically addressable with mRNA, making the platform nearly unlimited in scope.

Key players: Moderna and BioNTech are the platform leaders. Moderna generated over $6 billion in 2024 revenue (predominantly COVID vaccines) and is investing aggressively in oncology (personalized cancer vaccines in partnership with Merck), rare genetic diseases (cystic fibrosis, propionic acidemia), and respiratory combination vaccines (COVID + flu). BioNTech is pursuing oncology with similar intensity, leveraging its mRNA manufacturing expertise built during the pandemic.

The COVID hangover. Both companies face a strategic challenge: COVID vaccine revenue has declined sharply from its 2022 peak (Moderna peaked at $18 billion, BioNTech at $17 billion), and the pipeline must generate new revenue sources before cash reserves are depleted. This "post-COVID transition" creates M&A and partnering opportunities as mRNA companies seek collaborations to fund and de-risk their non-vaccine programs.

M&A relevance: mRNA companies are primarily targets for licensing deals rather than full acquisitions at current valuations. The platform nature of mRNA technology creates option value across multiple therapeutic areas, similar to the ADC platform premium. However, if personalized cancer vaccine data is definitive, a full acquisition of a mRNA platform company at a premium could become compelling for Big Pharma.

Personalized Cancer Vaccine

An mRNA-based therapy designed to train a patient's immune system to recognize and attack their specific tumor. The process involves sequencing the patient's tumor to identify unique mutations (neoantigens), designing an mRNA sequence encoding those neoantigens, manufacturing the personalized vaccine (typically within 4-6 weeks), and administering it to the patient in combination with checkpoint inhibitor immunotherapy. Moderna's cancer vaccine program (mRNA-4157/V940, in partnership with Merck) has shown promising Phase III data in melanoma, with a statistically significant reduction in recurrence and death. If successful across additional tumor types, personalized cancer vaccines would represent a new treatment paradigm in oncology with a market opportunity potentially exceeding $10 billion annually.

RNAi therapies use small interfering RNA molecules to silence specific genes, reducing the production of disease-causing proteins. Unlike traditional drugs that inhibit a protein after it has been made, RNAi prevents the protein from being made in the first place by targeting the messenger RNA that carries the instructions for that protein. Alnylam Pharmaceuticals is the category leader with five approved RNAi therapies generating over $2.5 billion in annual revenue and a validated GalNAc-conjugate delivery platform that enables subcutaneous administration.

Key advantage: RNAi platforms can progress from target identification to IND filing in approximately 18 months, dramatically faster than the 3-5 year preclinical timeline for traditional small molecule drug development. This speed exists because the same delivery technology (GalNAc for liver-targeted delivery) and the same molecular format (siRNA) can be applied to new targets simply by changing the RNA sequence. This creates a rapid pipeline expansion capability that is highly valued by acquirers.

The delivery challenge. The primary limitation of current RNAi technology is delivery: GalNAc conjugation works well for liver targets (which is why current approved RNAi therapies treat liver-related diseases like ATTR amyloidosis, hypercholesterolemia, and hepatitis B), but delivering siRNA to other organs (brain, muscle, lung, kidney) remains a major scientific challenge. Solving extrahepatic delivery would dramatically expand the addressable market for RNAi platforms and would likely trigger significant M&A activity.

Radioligand therapies (RLTs) combine a targeting molecule (peptide or antibody) with a radioactive isotope that delivers radiation directly to cancer cells. Unlike external beam radiation (which irradiates a broad area), RLTs deliver radiation with molecular precision, killing tumor cells wherever they are in the body, including metastatic sites that conventional radiation cannot reach.

Novartis's acquisition of Advanced Accelerator Applications ($3.9 billion in 2018) brought Lutathera (for neuroendocrine tumors), and the subsequent development of Pluvicto (lutetium-177 PSMA-617, for metastatic prostate cancer) validated the modality commercially. Pluvicto generated approximately $1.2 billion in 2024 revenue despite persistent supply constraints, demonstrating the strong commercial potential of RLTs.

Manufacturing and supply chain moat. RLTs require radioactive isotopes with short half-lives (hours to days), creating unique manufacturing and distribution logistics that represent the most significant barrier to entry in the modality. Lutetium-177 (the isotope used in Pluvicto and Lutathera) has a half-life of approximately 6.7 days, meaning the drug must be manufactured, shipped, and administered within a narrow window. This requires specialized nuclear pharmacies, rapid cold-chain logistics, and reliable isotope supply (which depends on nuclear reactors). These constraints limit the number of patients that can be treated at any given time and create a genuine competitive moat: even if a competitor develops a clinically superior RLT, it cannot commercialize without building equivalent supply chain infrastructure.

Protein degraders represent a fundamentally new mechanism: instead of inhibiting a disease-causing protein (the traditional approach), they recruit the cell's own protein disposal machinery (the ubiquitin-proteasome system) to destroy the target protein entirely. This approach can address "undruggable" targets that lack traditional binding sites for small molecule inhibitors, expanding the druggable proteome from an estimated 20% (with traditional approaches) to potentially 80%+.

PROTACs (Proteolysis-Targeting Chimeras) are bifunctional molecules with one end that binds the target protein and another end that binds an E3 ligase (the cell's protein tagging enzyme). By bringing the target protein and the E3 ligase into proximity, PROTACs cause the cell to tag the target for destruction. Molecular glues are simpler molecules that stabilize an interaction between the target protein and the E3 ligase without needing the bifunctional linker structure. Molecular glues are smaller, more drug-like, and easier to manufacture, but harder to discover rationally.

Key players include Arvinas (the PROTAC pioneer, with programs in breast and prostate cancer), Nurix Therapeutics, Kymera Therapeutics, and C4 Therapeutics. The modality is still primarily in early-to-mid clinical stages, with no approved PROTACs yet, but has attracted significant licensing deal activity from Big Pharma seeking to build positions in the technology.

The final article in the Biotech section covers orphan drugs and rare disease biotech, a sub-segment with uniquely favorable economics.